(52) determined that BRAF-mutant NSCLC patients treated with ICI plus chemotherapy resulted in better outcomes than those treated with chemotherapy or targeted therapy alone, suggesting ICI/chemo combinations could be given as first-line therapy for BRAF-mutant patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.